Navigation Links
MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
Date:2/2/2009

VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference on Monday, February 9, 2009 at 2:15 PM (EST) at the Hilton Waldorf Astoria in New York City. In addition to this presentation, the Company will host a breakfast meeting for invited investors and analysts at 7:30 AM (EST) on February 10th.

Interested parties can access links to live webcasts of both presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at https://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
2. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
3. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
4. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
5. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
6. MannKind to Present at the UBS Global Life Sciences Conference
7. MannKind Corporation Reports Second Quarter Financial Results
8. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
9. MannKind to Present at Upcoming Conferences
10. MannKind Corporation Reports First Quarter Financial Results
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):